Plasma total homocysteine levels in postmenopausal women with unstable coronary artery disease

Atherosclerosis

Volumn 151, Issue 2, 2000, Pages 423-431

  Nielsen, Niels Erik ^a   Brattström, Lars ^b   Hultberg, Björn ^c   Landgren, Finn ^b   Swahn, Eva ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^b KALMAR COUNTY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Coronary angiography; Covariates; Homocysteine; Odds ratio; ROC curve; Unstable coronary artery disease; Women

Indexed keywords

CREATININE; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE;

ADULT; AGE; AGED; AMINO ACID BLOOD LEVEL; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; VITAMIN BLOOD LEVEL;

AGED; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; FEMALE; HOMOCYSTEINE; HUMANS; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE; REFERENCE VALUES; RISK FACTORS; ROC CURVE;

EID: 0033855809     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(99)00416-5     Document Type: Article

References (52)

1. Mudd S., Levy H., Skovby F. Disorders of transulfuration. Scriver C.R.B.A., Sly W.S., Valle D. The Metabolic Basis of Inherited Disease. 7th ed. 1995;1279-1327 McGraw-Hill, New York.
2. Ueland P., Refsum H., Brattström L. Plasma homocysteine and cardiovascular disease. Francis Jr R.B. Atherosclerotic Cardiovascular Disease, Hemostasis, and Endothelial Function. 1992;183-236 Marcel Dekker Inc, New York, NY.
3. Stampfer M.J., Malinow M.R., Willett W.C. et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. J. Am. Med. Assoc. 268:1992;877-8781.
4. Arnesen E., Refsum H., Bonaa K.H., Ueland P.M., Forde O.H., Nordrehaug J.E. Serum total homocysteine and coronary heart disease. Int. J. Epidemiol. 24:1995;704-709.
5. Graham I.M., Daly L.E., Refsum H.M. et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. J. Am. Med. Assoc. 277:1997;1775-1781.
6. Boushey C.J., Beresford S.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J. Am. Med. Assoc. 274:1995;1049-1057.
7. Robinson K., Mayer E.L., Miller D.P. et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation. 92:1995;2825-2830.
8. Wu L.L., Wu J., Hunt S.C. et al. Plasma homocyst(e)ine as a risk factor for early familial coronary artery disease. Clin. Chem. 40:1994;552-561.
9. Mendis S., Athauda S.B., Takashi K. Association between hyperhomocysteinemia and ischemic heart disease in Sri Lankans. Int. J. Cardiol. 62:1997;221-225.
10. Schwartz S.M., Siscovick D.S., Malinow M.R. et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation. 96:1997;412-417.
11. Murphy-Chutorian D., Alderman E. The case that hyperhomocysteinemia is a risk factor for coronary artery disease. Am. J. Cardiol. 73:1994;705-707.
12. Aronow W.S., Ahn C. Association between plasma homocysteine and coronary artery disease in older persons. Am. J. Cardiol. 80:1997;1216-1218.
13. Malinow M., Sexton G., Averbuch M., Grossman M., Wilson D., Upson B. Homocyst(e)inemia in daily practice: levels in coronary artery disease. Coron. Artery Dis. 1:1990;215-220.
14. Verhoef P., Kok F.J., Kruyssen D.A. et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 17:1997;989-995.
15. Bots M.L., Launer L.J., Lindemans J., Hofman A., Grobbee D.E. Homocysteine, atherosclerosis and prevalent cardiovascular disease in the elderly: the Rotterdam study. J. Int. Med. 242:1997;339-347.
16. Dalery K., Lussier-Cacan S., Selhub J., Davignon J., Latour Y., Genest J. Homocysteine and coronary artery disease in French Canadian subjects: relation with vitamins B12, B6, pyridoxal phosphate, and folate. Am. J. Cardiol. 75:1995;1107-1111.
17. Nygard O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., Vollset S.E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N. Engl. J. Med. 337:1997;230-236.
18. Wald N.J., Watt H.C., Law M.R., Weir D.G., McPartlin J., Scott J.M. Homocysteine and ischemic heart disease: results of a prospective study with implications regarding prevention. Arch. Intern. Med. 158:1998;862-867.
19. Selhub J., Jacques P.F., Bostom A.G. et al. Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N. Engl. J. Med. 332:1995;286-291.
20. Perry I.J., Refsum H., Morris R.W., Ebrahim S.B., Ueland P.M., Shaper A.G. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 346:1995;1395-1398.
21. den Heijer M., Blom H.J., Gerrits W.B. et al. Is hyperhomocysteinaemia a risk factor for recurrent venous thrombosis. Lancet. 345:1995;882-885.
22. Alfthan G., Pekkanen J., Jauhiainen M. et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis. 106:1994;9-19.
23. Verhoef P., Hennekens C.H., Allen R.H., Stabler S.P., Willett W.C., Stampfer M.J. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. Am. J. Cardiol. 79:1997;799-801.
24. Evans R.W., Shaten B.J., Hempel J.D., Cutler J.A., Kuller L.H. Homocyst(e)ine and risk of cardiovascular disease in the Multiple Risk Factor Intervention Trial. Arterioscler. Thromb. Vasc. Biol. 17:1997;1947-1953.
25. Donner M.G., Klein G.K., Mathes P.B., Schwandt P., Richter W.O. Plasma total homocysteine levels in patients with early-onset coronary heart disease and a low cardiovascular risk profile. Metabolism. 47:1998;273-279.
26. Folsom A., Nieto J., McGovern P. et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B Vitamins. The Atherosclerosis risk in Communities (ARIC) Study. Circulation. 98:1998;204-210.
27. CASS Study Group. National Heart, Lung and Blood Institute Coronary Artery Surgery Study (CASS), Circulation 1981;63 (Monography 79).
28. Metz C.E. Some practical issues of experimental design and data analysis in radiological ROC studies. Invest. Radiol. 24:1989;234-245.
29. Grover S.A., Palmer C.S., Coupal L. Serum lipid screening to identify high-risk individuals for coronary death. The results of the Lipid Research Clinics prevalence cohort. Arch. Int. Med. 154:1994;679-684.
30. Grover S.A., Coupal L., Hu X.P. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work. J. Am. Med. Assoc. 274:1995;801-806.
31. Avins A.L., Browner W.S. Improving the prediction of coronary heart disease to aid in the management of high cholesterol levels: what a difference a decade makes. J. Am. Med. Assoc. 279:1998;445-449.
32. Zweig M.H. Apolipoproteins and lipids in coronary artery disease. Analysis of diagnostic accuracy using receiver operating characteristic plots and areas. Arch. Pathol. Lab. Med. 118:1994;141-144.
33. Nielsen NE, Olsson A, Swahn E. Plasma lipoprotein particle concentrations in postmenopausal women with unstable coronary artery disease. Analysis of diagnostic accuracy using receiver operating characteristics, J. Int. Med. 1999;in press.
34. Lijmer J., Hunink M., van den Dungen J., Loonstra J., Aj S. ROC analysis of noninvasive tests for peripheral arterial disease. Ultrasound Med. Biol. 22:1996;391-398.
35. Fragmin during Instability in Coronary Artery Disease (FRISC) study group. Low-molecular-weight heparin during instability in coronary artery disease, Lancet 1996;347:561-568.
36. Andersson A., Isaksson A., Brattstrom L., Hultberg B. Homocysteine and other thiols determined in plasma by HPLC and thiol-specific postcolumn derivatization. Clin. Chem. 39:1993;1590-1597.
37. Swets J.A. Measuring the accuracy of diagnostic systems. Science. 240:1988;1285-1293.
38. Karlsson J., Bjorkholm A., Nylander E., Ohlsson J., Swahn E., Wallentin L. ST-changes in ECG at rest or during exercise indicate a high risk of severe coronary lesions after an episode of unstable coronary artery disease. Int. J. Cardiol. 42:1993;47-55.
39. Egerton W., Silberberg J., Crooks R., Ray C., Xie L., Dudman N. Serial measures of plasma homocyst(e)ine after acute myocardial infarction. Am. J. Card. 77:1996;759-761.
40. Landgren F., Israelsson B., Lindgren A., Hultberg B., Andersson A., Brattström L. Plasma homocysteine in acute myocardial infarction: homocysteine-lowering effect of folic acid. J. Int. Med. 237:1995;381-388.
41. Refsum H., Ueland P.M., Nygard O., Vollset S.E. Homocysteine and cardiovascular disease. Ann. Rev. Med. 49:1998;31-62.
42. Refsum H, Guttormsen A, Fiskerstrand T, Ueland PM. Hyperhomocysteinemia in terms of steady-state kinetics, Eur. J. Pediatr. 1998;157:S45-S49.
43. Task Force of the European Society of Cardiology. Management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology, Eur. Heart. J. 1997;18:394-413.
44. Brattstrom L., Lindgren A., Israelsson B., Andersson A., Hultberg B. Homocysteine and cysteine: determinants of plasma levels in middle-aged and elderly subjects. J. Int. Med. 236:1994;633-641.
45. Frosst P., Blom H.J., Milos R. et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10:1995;111-113. Letter.
46. Jacques P.F., Bostom A.G., Williams R.R. et al. Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation. 93:1996;7-9.
47. Harmon D.L., Woodside J.V., Yarnell J.W. et al. The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. Q. J. Med. 89:1996;571-577.
48. Ma J., Stampfer M.J., Hennekens C.H. et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation. 94:1996;2410-2416.
49. Verhoef P., Kok F.J., Kluijtmans L.A. et al. The 677C - >T mutation in the methylenetetrahydrofolate reductase gene: associations with plasma total homocysteine levels and risk of coronary atherosclerotic disease. Atherosclerosis. 132:1997;105-113.
50. Kluijtmans L.A., Kastelein J.J., Lindemans J. et al. Thermolabile methylenetetrahydrofolate reductase in coronary artery disease. Circulation. 96:1997;2573-2577.
51. Brattström L., Wilcken D., Öhrvik J., Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease - the result of a meta analysis. Circulation. 98:1998;2520-2526.
52. Brattström L., Zhang Y., Hurtig M. et al. A common methylenetetrahydrofolate reductase gene mutation (C677T/MTHFR) and longevity. Atherosclerosis. 141:1998;315-319.